Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds

摘要

A method of predicting the response of a subject who has, is suspected of having, or who is at risk of developing thyroid cancer or kidney cancer, to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof, the method comprising: providing a biological sample obtained from the subject after therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof; and measuring the concentration of ANGPT2 protein in the biological sample, a reduced concentration, compared to a control, of ANGPT2 being predictive that the subject will respond to therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof.